Marth was trying to convince listeners that the involvement of OBP means sameness has been established and hence the review of the ANDA by the Office of Generic Drugs (OGD) is complete; however, I don’t think Marth’s logic stands up to scrutiny because the interaction between OGD and OBP is more of a back-and-forth thing than a sequential process.
Bill Marth himself is on record that the interaction between OGD and OBP is back and forth; this is what Marth said at the Goldman Sachs investor conference on January 8, 2009 (#msg-35090820):
I rest my case.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.